3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Uterine Cervical Neoplasms
3
Prostatic Neoplasms
3
Urinary Bladder Neoplasms
2
Sarcoma
2
Pancreatic Neoplasms
2
Breast Neoplasms
2
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Ewing
1
Prostate Adenocarcinoma
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Male Urogenital Diseases
1
Lymphedema
1
Lung Neoplasms
1
Gallbladder Neoplasms
1
Financial Stress
1
Female Urogenital Diseases
1
Endometrial Neoplasms
1
Encopresis
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Carcinoma In Situ
1
Interventions
pembrolizumab
36
Bevacizumab
25
Cyclophosphamide
22
Blood Specimen Collection
18
Nivolumab
17
Carboplatin
15
Standard of Care
14
Paclitaxel
14
atezolizumab
13
Gemcitabine
13
Exercise
13
Pemetrexed
11
Fluorouracil
11
Doxorubicin
11
Cisplatin
11
Cetuximab
10
Radiotherapy
9
Oxaliplatin
9
Magnetic Resonance Spectroscopy
9
Leucovorin
9
Docetaxel
9
durvalumab
8
abemaciclib
8
Temozolomide
8
Surveys and Questionnaires
8
Rituximab
8
Prednisone
8
Biopsy
8
130-nm albumin-bound paclitaxel
8
olaparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Radiation Dose Hypofractionation
×
90 days
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled